Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

701 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial.
Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Magbanua MJM, O'Grady N, Hirst G; I-SPY 2 TRIAL Investigators; Asare S, Tripathy D, Berry D, Esserman L, Chien AJ, Petricoin EF 3rd, van 't Veer L. Wolf DM, et al. Among authors: tripathy d. NPJ Breast Cancer. 2020 Oct 2;6:48. doi: 10.1038/s41523-020-00189-2. eCollection 2020. NPJ Breast Cancer. 2020. PMID: 33083527 Free PMC article.
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, Wolf D, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Livasy C, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, Au A, Hylton N; I-SPY 1 TRIAL Investigators. Esserman LJ, et al. Among authors: tripathy d. Breast Cancer Res Treat. 2012 Apr;132(3):1049-62. doi: 10.1007/s10549-011-1895-2. Epub 2011 Dec 25. Breast Cancer Res Treat. 2012. PMID: 22198468 Free PMC article.
Adoption, acceptability, and accuracy of an online clinical trial matching website for breast cancer.
Cohen E, Belkora J, Tyler J, Schreiner J, Deering MJ, Grama L, Duggan B, Illi J, Pederson J, Anand A, Teng A, McCreary E, Moore D, Tripathy D, Hogarth M, Lieberman M, Park J, Esserman L. Cohen E, et al. Among authors: tripathy d. J Med Internet Res. 2012 Jul 11;14(4):e97. doi: 10.2196/jmir.1855. J Med Internet Res. 2012. PMID: 22784878 Free PMC article.
Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk.
Magbanua MJM, Li W, Wolf DM, Yau C, Hirst GL, Swigart LB, Newitt DC, Gibbs J, Delson AL, Kalashnikova E, Aleshin A, Zimmermann B, Chien AJ, Tripathy D, Esserman L, Hylton N, van 't Veer L. Magbanua MJM, et al. Among authors: tripathy d. NPJ Breast Cancer. 2021 Mar 25;7(1):32. doi: 10.1038/s41523-021-00239-3. NPJ Breast Cancer. 2021. PMID: 33767190 Free PMC article.
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.
Yee D, Isaacs C, Wolf DM, Yau C, Haluska P, Giridhar KV, Forero-Torres A, Jo Chien A, Wallace AM, Pusztai L, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Kemmer K, Yung RL, Pohlmann PR, Tripathy D, Clark AS, Han HS, Nanda R, Khan QJ, Edmiston KK, Petricoin EF, Stringer-Reasor E, Falkson CI, Majure M, Mukhtar RA, Helsten TL, Moulder SL, Robinson PA, Wulfkuhle JD, Brown-Swigart L, Buxton M, Clennell JL, Paoloni M, Sanil A, Berry S, Asare SM, Wilson A, Hirst GL, Singhrao R, Asare AL, Matthews JB, Hylton NM, DeMichele A, Melisko M, Perlmutter J, Rugo HS, Fraser Symmans W, Van't Veer LJ, Berry DA, Esserman LJ. Yee D, et al. Among authors: tripathy d. NPJ Breast Cancer. 2021 Oct 5;7(1):131. doi: 10.1038/s41523-021-00337-2. NPJ Breast Cancer. 2021. PMID: 34611148 Free PMC article.
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial.
Clark AS, Yau C, Wolf DM, Petricoin EF, van 't Veer LJ, Yee D, Moulder SL, Wallace AM, Chien AJ, Isaacs C, Boughey JC, Albain KS, Kemmer K, Haley BB, Han HS, Forero-Torres A, Elias A, Lang JE, Ellis ED, Yung R, Tripathy D, Nanda R, Wulfkuhle JD, Brown-Swigart L, Gallagher RI, Helsten T, Roesch E, Ewing CA, Alvarado M, Crane EP, Buxton M, Clennell JL, Paoloni M, Asare SM, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Melisko M, Perlmutter J, Rugo HS, Schwab RB, Symmans WF, Hylton NM, Berry DA, Esserman LJ, DeMichele AM. Clark AS, et al. Among authors: tripathy d. Nat Commun. 2021 Nov 5;12(1):6428. doi: 10.1038/s41467-021-26019-y. Nat Commun. 2021. PMID: 34741023 Free PMC article.
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.
Magbanua MJM, Brown Swigart L, Ahmed Z, Sayaman RW, Renner D, Kalashnikova E, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Asare S, Liu MC, Albain K, Chien AJ, Forero-Torres A, Isaacs C, Nanda R, Tripathy D, Rodriguez A, Sethi H, Aleshin A, Rabinowitz M, Perlmutter J, Symmans WF, Yee D, Hylton NM, Esserman LJ, DeMichele AM, Rugo HS, van 't Veer LJ. Magbanua MJM, et al. Among authors: tripathy d. Cancer Cell. 2023 Jun 12;41(6):1091-1102.e4. doi: 10.1016/j.ccell.2023.04.008. Epub 2023 May 4. Cancer Cell. 2023. PMID: 37146605 Free article.
Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan.
Zhao M, DiPeri TP, Raso MG, Zheng X, Rizvi YQ, Evans KW, Yang F, Akcakanat A, Roberto Estecio M, Tripathy D, Dumbrava EE, Damodaran S, Meric-Bernstam F. Zhao M, et al. Among authors: tripathy d. NPJ Breast Cancer. 2023 Aug 11;9(1):66. doi: 10.1038/s41523-023-00573-8. NPJ Breast Cancer. 2023. PMID: 37567892 Free PMC article.
701 results